Blood recipients and CJD: to notify or not to notify, that is the question.
Should Recipients who have received Blood from a person who developed Creutzfeldt-Jakob disease be notified, even though there is no proof the disease will be transmitted? Does notification simply cause unnecessary anxiety? Two recipients explained their polar-opposite positions during a recent Health Canada conference.
Sibbald
B
B
D000368:Aged; D001294:Attitude to Health; D016913:Blood Component Transfusion / Q000009:adverse effects*; D002170:Canada; D007562:Creutzfeldt-Jakob Syndrome / Q000635:transmission*; D030881:Disclosure; D018563:Disease Notification; D033002:Duty to Recontact; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018570:Risk Assessment; D012307:Risk Factors; D014342:Truth Disclosure